Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H24F3NO5S |
Molecular Weight | 411.436 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN([C@@H]1[C@@H](O)C(C)(C)OC2=CC=C(OCCCC(F)(F)F)C=C12)S(C)(=O)=O
InChI
InChIKey=SRZRLJWUQFIZRH-LSDHHAIUSA-N
InChI=1S/C17H24F3NO5S/c1-16(2)15(22)14(21(3)27(4,23)24)12-10-11(6-7-13(12)26-16)25-9-5-8-17(18,19)20/h6-7,10,14-15,22H,5,8-9H2,1-4H3/t14-,15+/m0/s1
Molecular Formula | C17H24F3NO5S |
Molecular Weight | 411.436 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://adisinsight.springer.com/drugs/800013615Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11689069 | https://www.ncbi.nlm.nih.gov/pubmed/15795798
Sources: http://adisinsight.springer.com/drugs/800013615
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11689069 | https://www.ncbi.nlm.nih.gov/pubmed/15795798
HMR 1556 is a blocker of the slow component of the delayed rectifier potassium current (IKs). It is being preclinically developed by sanofi-aventis in Germany as an oral agent for the treatment of atrial fibrillation.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11689069 |
0.12 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Inhibition of IKs channels by HMR 1556. | 2000 Dec |
|
Synthesis and activity of novel and selective I(Ks)-channel blockers. | 2001 Nov 8 |
|
HMR 1556, a potent and selective blocker of slowly activating delayed rectifier potassium current. | 2003 Jan |
|
The new selective I(Ks)-blocking agent HMR 1556 restores sinus rhythm and prevents heart failure in pigs with persistent atrial fibrillation. | 2005 May |
Patents
Sample Use Guides
Pigs: HMR 1556 (30 mg/kg, p.o., 10 days) efficiently and safely restores sinus rhythm and prevents heart failure in a model of persistent atrial fibrillation.
Rabbit: HMR 1556 (1 mg/kg/hr i.v.).
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16133261
HMR1556 inhibited 48% of the outward current with an IC(50) of 7 uM in insulin-secreting INS-1 cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:42:36 GMT 2023
by
admin
on
Fri Dec 15 16:42:36 GMT 2023
|
Record UNII |
4IF4R31066
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
223749-46-0
Created by
admin on Fri Dec 15 16:42:36 GMT 2023 , Edited by admin on Fri Dec 15 16:42:36 GMT 2023
|
PRIMARY | |||
|
4IF4R31066
Created by
admin on Fri Dec 15 16:42:36 GMT 2023 , Edited by admin on Fri Dec 15 16:42:36 GMT 2023
|
PRIMARY | |||
|
DTXSID801105017
Created by
admin on Fri Dec 15 16:42:36 GMT 2023 , Edited by admin on Fri Dec 15 16:42:36 GMT 2023
|
PRIMARY | |||
|
9887834
Created by
admin on Fri Dec 15 16:42:36 GMT 2023 , Edited by admin on Fri Dec 15 16:42:36 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |